Zobrazeno 1 - 10
of 115
pro vyhledávání: '"A. L. Bakulev"'
Autor:
A. E. Karamova, O. Y. Olisova, A. L. Bakulev, M. M. Kokhan, V. R. Khairutdinov, E. V. Sokolovskiy, M. M. Khobeych
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 97, Iss 5, Pp 18-25 (2021)
Currently there are a large number of psoriasis classifications, slightly different from each other, used worldwide. Some of these classifications contain the disease forms allocated descriptively, without the pathogenesis characteristics in their ba
Externí odkaz:
https://doaj.org/article/3e9067280d404d5788071d09fa8cefbf
Autor:
T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 1, Pp 47-55 (2021)
Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Herein, we report the accumulated efficacy data and safety findings of 54-week
Externí odkaz:
https://doaj.org/article/4cf1afa40e2e4cf69285a9061fcc7d8f
Autor:
T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 5, Pp 480-488 (2020)
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Here, we present the results of the 24-weeks double blind perio
Externí odkaz:
https://doaj.org/article/140fe3665cd14bf7adce314acddb0275
Autor:
D. I. Abdulganieva, A. L. Bakulev, E. A. Belousova, A. V. Veselov, T. V. Korotaeva, A. M. Lila, E. Yu. Loginova, E. V. Sokolovskiy, M. M. Khobeish, M. V. Shapina, O. B. Shchukina
Publikováno v:
Современная ревматология, Vol 14, Iss 3, Pp 7-18 (2020)
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and frequently lead to disability; therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorabl
Externí odkaz:
https://doaj.org/article/e338338809204dbd8dc7334092900e55
Autor:
A. A. Kubanov, A. L. Bakulev, M. I. Gluzmin, M. M. Kokhan, L. S. Kruglova, N. S. Rudneva, O. Yu. Olisova, E. V. Sokolovsky, M. M. Khobeish
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 5, Pp 50-57 (2019)
Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these dise
Externí odkaz:
https://doaj.org/article/644b2e5f432b4bde8ed13f8ba3572058
Autor:
A. L. Bakulev, D. D. Petrunin
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 4, Pp 87-93 (2019)
Introduction. Currently there is insufficient data regarding routine use of various topical treatments for plaque psoriasis outside from randomized clinical trials, their efficacy, cost-effectiveness and perception by dermatologists and patients. The
Externí odkaz:
https://doaj.org/article/f6dcf432cd454104a89f8fe96453c456
Autor:
A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, V. R. Khairutdinov, M. M. Kokhan, A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 3, Pp 54-64 (2019)
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimat
Externí odkaz:
https://doaj.org/article/37963b61b86444bb812f998927a4eb67
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 4, Pp 48-56 (2019)
The high incidence of melanoma and unsatisfactory results of its treatment in some cases make the issue of timely diagnostics of pre-melanoma skin pathology, in particular the identification of pre-melanoma pigmented nevi, of great importance and can
Externí odkaz:
https://doaj.org/article/5ae87d5488b84fdbb5c877ee60d42b40
Autor:
O. V. Kolokolov, A. L. Bakulev, A. A. Shuldyakov, N. S. Makarov, I. V. Sitkali, A. M. Kolokolova, S. S. Kravchenya
Publikováno v:
Клиническая практика, Vol 10, Iss 2, Pp 74-84 (2019)
The modern information on the epidemiology, pathogenesis, clinical manifestations, diagnosis and pain management in HHV-3-associated neuro-infection is presented. The criteria for the phased diagnostics and approaches to the rational therapy for shin
Externí odkaz:
https://doaj.org/article/bab7825d8d234adf97a2d4468b7230d0
Autor:
A. A. Kubanov, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, E. V. Sokolovskiy, M. M. Kokhan, A. V. Artemyeva, E V. Chernyaeva, R. A. Ivanov
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 95, Iss 2, Pp 15-28 (2019)
Netakimab, the original monoclonal antibody against IL-17A, is an innovative drug for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy. Netakimab was approved in Russian Federa
Externí odkaz:
https://doaj.org/article/4007b553226b4cd19f7d282f1ce493c9